Our experience in both in vitro and in vivo systems leads us to conclude that drugs of beta1 and beta2 activity inhibit the release of histamine by virtue of their capacity to stimulate adenyl cyclase. Kinetic studies of beta agonistic drugs reveal a rapid but short-lived increase in intercellular cyclic AMP which is reflected in the requirement for beta agonists to be introduced at virtually the same time antigen is presented to the shock organ. Kinetics and relative pharmacologic activity of selective beta2 agonists have not yet been studied in the two systems described, but remain as the next logical steps to be taken in the investigation of the relative activity and kinetic behavior of receptor specific sympathomimetics.
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
- Critical Care and Intensive Care Medicine
- Cardiology and Cardiovascular Medicine